Aktienanalyse zu Cadrenal Therapeutics Inc (CVKD)CVKDCadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cadrenal Therapeutics Inc (CVKD) is currently not a good buy due to its low price of $1.54, which is significantly down 78.99% year-to-date, indicating substantial market skepticism. The RSI is at 23.316, suggesting the stock is oversold, but this could also indicate continued weakness. The forward P/E ratio is 0, reflecting uncertainty in future earnings, and the company has reported consistent net losses, with the latest quarterly net income at -2,496,540 USD.